The collaboration brings together two highly complementary technology platforms: abc biopply's proprietary 3D CoSeedis™ Humanized Multi-Organoid Models and extensive CRO expertise, and VoxCell's innovative vascularized and perfusable tissue models. Together, the companies aim to create new opportunities for pharmaceutical, biotechnology, and academic partners seeking more predictive, human-relevant approaches to preclinical research.

Extending Human-Based Fit-for Purpose Development Activities
As the pharmaceutical industry increasingly embraces New Approach Methodologies (NAMs), the need for fit-for-purpose models that provide robust and translationally relevant data has never been greater. The proposed collaboration is designed to address this challenge by combining advanced organoid biology with vascularization and perfusion technologies that more closely mimic human physiology.

The partnership responds to growing demand for New Approach Methodologies (NAMs) that improve the human relevance of preclinical testing and reduce reliance on animal models. VoxCell's models provide perfused, endothelial-lined vasculature inside 3D human tissues, a capability that complements abc biopply's humanized organoid platform and preclinical expertise. The companies also intend to explore the longer-term integration of VoxCell's vascularization technology with abc biopply's CoSeedis organoid models.

This approach aligns closely with both companies’ vision of providing fully integrated preclinical development solutions built around a fit-for-purpose philosophy.  Rather than promoting a single technology as the answer to every scientific question, the partners believe that the highest-quality IND-relevant data are generated when the right model is applied at the right stage of drug development. The extended service portfolio of abc biopply integrating now advanced vascularization technology models from VoxCell enables customers to access tailored development strategies that maximize predictability while optimizing time, cost, and resource utilization.

Exploring the Future of Vascularized Multi-Organoid Systems
Beyond commercialization opportunities, the two companies will evaluate longer-term joint technology development initiatives. By combining abc biopply's expertise in standardized humanized multi-organoid systems with VoxCell's vascularization and perfusion technologies, the companies envision creating a new generation of human-relevant models capable of bridging the translational gap between traditional in vitro systems and clinical outcomes.

Leadership Perspectives
Arne Faisst, Founder and CEO of abc biopply AG, commented: "The future of drug development is not about choosing between 2D models, organoids, vascularized tissues, or animal studies. It is about intelligently integrating complementary technologies into fit-for-purpose development strategies. We believe the combination of VoxCell's vascularization expertise with our 3D CoSeedis™ Humanized Multi-Organoid Models has the potential to create highly predictive and clinically relevant preclinical models that deliver better decision-making and ultimately better outcomes for patients."

Dr. Karolina Valente, CEO and CSO of VoxCell added: “abc biopply brings deep organoid expertise and an established preclinical service base in Europe, and we are excited to make our vascularized human tissue models available to their clients. Adding perfused human vasculature to their platform gives drug developers a more predictive view of efficacy and safety, and it brings human-relevant models to more programs earlier.”